Welcome to LookChem.com Sign In|Join Free
  • or
Oxazole, 5-ethyl-4-(iodomethyl)-2-(4-methylphenyl)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

752212-77-4

Post Buying Request

752212-77-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

752212-77-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 752212-77-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,5,2,2,1 and 2 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 752212-77:
(8*7)+(7*5)+(6*2)+(5*2)+(4*1)+(3*2)+(2*7)+(1*7)=144
144 % 10 = 4
So 752212-77-4 is a valid CAS Registry Number.

752212-77-4Upstream product

752212-77-4Downstream Products

752212-77-4Relevant academic research and scientific papers

2-{-3,'2-(PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYL METHOXY}-PROPIONIC ACID DERIVATIVES USED AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES

-

, (2008/06/13)

The present invention comprises compounds and compositions for the treatment of metabolic disorders and more particularly, those insulin-related metabolic disorders of the blood such as hyperlipidemia, diabetes, insulin-resistence and the like comprising acetic acid derivatives with cyclohexylmethoxy substituents and their salts. Known as peroxisome proliferator-activated receptors (PPAR) agonists/antagonists, the invention relates to compounds of formula I wherein the various substituent R-groups are more specifically defined herein.

2 - { - 3 2 - (PHENYL)-OXAZOL-4-YLMETHOXYL-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USED AS PPAR LIGANDS (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES

-

Page/Page column 35, (2008/06/13)

The invention relates to compounds of formula (I), wherein R1 represents H, (C1-C6)-alkyl; R2 represents H, an O-(C1-C3)-alkyl, CF3; or R1 and R2 represent, together with the phenyl-ring, a condensed naphthyl; R3 represents a (C1-C6)-alkyl; R4 represents a (C1-C6)-alkyl, benzyl; R5 represents H, (C1-C6)-alkyl. The invention also relates to the physiologically compatible salts thereof, solvates and physiologically functional derivatives. The inventive compounds are suitable for treating and/or preventing disorders of the fatty acid metabolism and disorders of glucose utilization in addition to disorders, in which insulin resistance plays a part.

2 - {-3-`2-(PHENYL)-OXAZOL-4-YLMETHOXYMETHYL!-CYCLOHEXYLMETHOXY}-PROPIONIC ACID DERIVATIVES USED AS PPAR LIGANDES (PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS) FOR THE TREATMENT OF HYPERLIPIDAEMIE AND DIABETES

-

Page/Page column 36, (2008/06/13)

The invention relates to compounds of formula (I), wherein R represents H, CF3; R1 represents H, CF3, a (C1-C6)-alkyl, a phenyl, a phenoxy; R2 represents H, a (C1-C4)-alkyl, O-(C1-C4)-alkyl, CF3; or R1 and R2 represent, together with the phenyl-ring, a condensed naphthyl; R3 represents a (C1-C6)-alkyl; R4 represents a (C1-C6)-alkyl, benzyl; R5 represents H, a (C1-C6)-alkyl. The invention also relates to the physiologically compatible salts thereof, solvates and physiologically functional derivatives. The inventive compounds are suitable for treating and/or preventing disorders of the fatty acid metabolism and disorders of glucose utilization in addition to disorders, in which insulin resistance plays a part.

Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals

-

Page/Page column 24, (2008/06/13)

Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 752212-77-4